Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

This publication has 18 references indexed in Scilit:

• Treatment of recurrent small cell lung cancer
  Hematology/Oncology Clinics of North America, 2004
• Bcl-2 as a Target for Overcoming Chemoresistance in Small-Cell Lung Cancer
  Clinical Lung Cancer, 2003
• Role ofBcl-2, Bax, andBak in spontaneous apoptosis and proliferation in neuroendocrine lung tumors: Immunohistochemical study
  Bulletin of Experimental Biology and Medicine, 2000
• NF-κB Activation Is Related to the Resistance of Lung Cancer Cells to TNF-α-Induced Apoptosis
  Biochemical and Biophysical Research Communications, 2000
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
  Nature Medicine, 1999
• Second-line chemotherapy for relapsed small cell lung cancer
  Japanese Journal of Clinical Oncology, 1997
• Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
  Journal of Clinical Oncology, 1997
• Bcl-2 Oncoprotein Expression Is Increased Especially in the Portion of Small Cell Carcinoma within the Combined Type of Small Cell Lung Cancer
  Tumor Biology, 1996
• Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB
  Nature, 1993
• Activation in vitro of NF-κB" by phosphorylation of its inhibitor IκB"
  Nature, 1990